Featured Publications
Phenotypes of sleep health among adults with chronic heart failure in a randomized controlled trial of cognitive behavioral therapy for insomnia
Jeon S, Conley S, O'Connell M, Wang Z, Redeker N. Phenotypes of sleep health among adults with chronic heart failure in a randomized controlled trial of cognitive behavioral therapy for insomnia. Sleep Health 2024 PMID: 39482227, DOI: 10.1016/j.sleh.2024.09.006.Peer-Reviewed Original ResearchEmergency department visitsRandomized controlled trial of cognitive behavioral therapyCognitive behavioral therapyTrial of cognitive behavioral therapyDepartment visitsHealth phenotypesRandomized controlled trialsBehavioral therapyProportion of participantsGeneralized estimating equationsCox proportional hazards modelsProportional hazards modelCircadian quotientLinear mixed modelsLower fatigueGeneralized linear mixed modelsSecondary analysisWalking distanceSleep healthCollected hospitalFunctional performanceSleep phenotypesPoor sleepAdverse healthHeart failure outcomes
2020
Empagliflozin in Heart Failure
Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in Heart Failure. Circulation 2020, 142: 1028-1039. PMID: 32410463, PMCID: PMC7521417, DOI: 10.1161/circulationaha.120.045691.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsNeurohormonal activationHeart failureRenal dysfunctionBlood volumeHeart failure-related outcomesPlacebo-controlled crossover studyType 2 diabetes mellitusProximal tubular siteHeart failure outcomesStable heart failureUrinary glucose excretionUric acid levelsElectrolyte wastingEmpagliflozin monotherapyOral empagliflozinPlacebo periodStudy drugGlucose excretionNatriuretic effectPotassium wastingTubular sitesDiabetes mellitusFractional excretion